Matsuo Koji, Omatsu Kohei, Ross Malcolm S, Johnson Marian S, Yunokawa Mayu, Klobocista Merieme M, Im Dwight D, Bush Stephen H, Ueda Yutaka, Takano Tadao, Blake Erin A, Hasegawa Kosei, Baba Tsukasa, Shida Masako, Satoh Shinya, Yokoyama Takuhei, Machida Hiroko, Adachi Sosuke, Ikeda Yuji, Iwasaki Keita, Miyake Takahito M, Yanai Shiori, Nishimura Masato, Nagano Tadayoshi, Takekuma Munetaka, Takeuchi Satoshi, Pejovic Tanja, Shahzad Mian Mk, Ueland Frederick R, Kelley Joseph L, Roman Lynda D
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, CA, USA.
Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Gynecol Oncol. 2017 Apr;145(1):78-87. doi: 10.1016/j.ygyno.2017.02.001. Epub 2017 Feb 16.
To examine recurrence patterns in women with stage I uterine carcinosarcoma (UCS) stratified by adjuvant therapy pattern.
We examined 443 cases of stage I UCS derived from a retrospective cohort of 1192 UCS cases from 26 institutions. Adjuvant therapy patterns after primary hysterectomy-based surgery were correlated to recurrence patterns.
The most common adjuvant therapy was chemotherapy alone (41.5%) followed by chemotherapy/radiotherapy (15.8%) and radiotherapy alone (8.4%). Distant-recurrence was the most common recurrence pattern (5-year cumulative rate, 28.1%) followed by local-recurrence (13.3%). On multivariate analysis, chemotherapy but not radiotherapy remained an independent prognostic factor for decreased risk of local-recurrence (5-year cumulative rates 8.7% versus 19.8%, adjusted-hazard ratio [HR] 0.46, 95% confidence interval [CI] 0.25-0.83, P=0.01) and distant-recurrence (21.2% versus 38.0%, adjusted-HR 0.41, 95%CI 0.27-0.62, P<0.001). The chemotherapy/radiotherapy group had a lower 5-year cumulative local-recurrence rate compared to the chemotherapy alone group but it did not reach statistical significance (5.1% versus 10.1%, adjusted-HR 0.46, 95%CI 0.13-1.58, P=0.22). Radiotherapy significantly decreased local-recurrence when tumors had high-grade carcinoma, sarcoma component dominance, and deep myometrial tumor invasion (all, P<0.05); and combining radiotherapy with chemotherapy was significantly associated with decreased local-recurrence compared to chemotherapy alone in the presence of multiple risk factors (5-year cumulative rates, 2.5% versus 21.8%, HR 0.12, 95%CI 0.02-0.90; P=0.013) but not in none/single factor (P=0.36).
Adjuvant chemotherapy appears to be effective to control both local- and distant-recurrences in stage I UCS; adding radiotherapy to chemotherapy may be effective to control local-recurrence when the tumor exhibits multiple risk factors.
按辅助治疗模式对Ⅰ期子宫癌肉瘤(UCS)女性患者的复发模式进行研究。
我们对来自26家机构的1192例UCS病例的回顾性队列中的443例Ⅰ期UCS病例进行了研究。以子宫全切术为主的手术后辅助治疗模式与复发模式相关。
最常见的辅助治疗是单纯化疗(41.5%),其次是化疗/放疗(15.8%)和单纯放疗(8.4%)。远处复发是最常见的复发模式(5年累积率为28.1%),其次是局部复发(13.3%)。多因素分析显示,化疗而非放疗仍是局部复发风险降低的独立预后因素(5年累积率分别为8.7%和19.8%,校正风险比[HR]为0.46,95%置信区间[CI]为0.25 - 0.83,P = 0.01)以及远处复发风险降低的独立预后因素(21.2%和38.0%,校正HR为0.41,95%CI为0.27 - 0.62,P < 0.001)。与单纯化疗组相比,化疗/放疗组的5年累积局部复发率较低,但未达到统计学意义(5.1%对10.1%,校正HR为0.46,95%CI为0.13 - 1.58,P = 0.22)。当肿瘤具有高级别癌、肉瘤成分占优势以及肌层深部肿瘤浸润时,放疗可显著降低局部复发率(均P < 0.05);在存在多种危险因素的情况下,与单纯化疗相比,放疗联合化疗与局部复发率降低显著相关(5年累积率分别为2.5%和21.8%,HR为0.12,95%CI为0.02 - 0.90;P = 0.013),但在无/单一危险因素时则无此相关性(P = 0.36)。
辅助化疗似乎对控制Ⅰ期UCS的局部和远处复发均有效;当肿瘤存在多种危险因素时,化疗联合放疗可能对控制局部复发有效。